Silencing ANRIL can suppress cell proliferation, promote cell apoptosis, and reduce the expression of drug transporter MRP1 and ABCC2, thus enhancing the cisplatin-sensitivity of oral squamous cell carcinoma cells [33]. This evidence concerns the gene CDKN2B-AS1 and squamous cell carcinoma.